

Applicants: Tove Ringerike et al.
U.S. Serial No.: Not Yet Known
Filed: Herewith
Page 12

Information Disclosure Statement

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the following documents which are listed on Form PTO-1449 (**Exhibit D**) and are also listed below.

This Information Disclosure Statement is being submitted pursuant to 37 C.F.R. §1.97(b)(3) before the mailing of a first Office Action on the merits. Thus, this Information Disclosure Statement should be entered and considered.

The subject application is a \$371 national stage application based on PCT International Application No. PCT/PL2004/000075, filed September 26, 2004, designating the United States and claiming priority of PCT International Application No. PCT/PL03/00098. Copies of the documents listed below as items 1-5 have previously been cited in the International Search Report in connection with International Application No. PCT/PL2004/000075. Copies of the previously cited documents are therefore, not provided.

1. U.S. Patent Application Publication No. 2002/132290 (Frazer Kelly, et al.), September 19, 2002;
2. U.S. Patent Application Publication No. 2003/149254 (Anderson David et al.), August 7, 2003;
3. U.S. Patent Application Publication No. 2004/029109 (Lai Derhsing), February 12, 2004;
4. PCT International Publication No. WO 95/31722 (Ligand Pharmaceuticals, Inc.), November 23, 1995; and
5. PCT International Publication No. WO 97/39722 (T Cell Sciences, Inc.; Lin, Augustine, Y.-T; Scott, W; Batzer), October 30, 1997.


Applicants: Tove Ringerike et al.
U.S. Serial No.: Not Yet Known
Filed: Herewith
Page 13

Applicants request that the Examiner review the references and make them of record in the subject application.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee, other than the enclosed filing fee of \$900.00, is deemed necessary in connection with the filing of this Preliminary Amendment. If any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,


Gary J. Gershik
Registration No. 39,992
Attorney for the Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

Serial No. 26
Not Yet Known

Group

***EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.